CARB-X, a public–private partnership aimed at bolstering the antibiotic pipeline, funded a diverse set of 17 early-stage drug development projects in its first year.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Preclinical antibiotic pipeline gets a pick-me-up. Nat Rev Drug Discov 16, 741–742 (2017). https://doi.org/10.1038/nrd.2017.213
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.213
This article is cited by
-
Hürden und Aussichten neuer antimikrobieller Konzepte in Forschung und Entwicklung
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2018)